Surmodics (NASDAQ:SRDX) (NASDAQ: SRDX) is a medical technology company specializing in surface modification and drug-eluting coating technologies for medical devices and in vitro diagnostic applications. The company’s core expertise lies in polymer-based solutions that enhance device performance, including hydrophilic coatings to improve catheter lubricity and drug-delivery coatings for cardiovascular and peripheral vascular stents. Surmodics also offers proprietary diagnostic assay platforms and automation solutions for clinical laboratories.
Surmodics’ product portfolio is organized around two main segments: medical device and in vitro diagnostics. In the medical device segment, the company provides therapeutic delivery coatings, surface modifiers, and adhesive technologies for customers developing implants, guide wires, and catheters. On the diagnostics side, Surmodics supplies reagents, assay calibrators, and control materials, as well as instrumentation used in immunoassay and molecular diagnostic workflows.
Founded in Eden Prairie, Minnesota, in 1986, Surmodics has expanded its operations to serve a global client base across North America, Europe, and Asia. The company’s research and development efforts focus on advancing biocompatible polymers and next-generation delivery systems, while its manufacturing facilities adhere to international quality standards. Surmodics collaborates with a diverse set of medical device OEMs, contract manufacturers, and diagnostic companies to bring customized surface and assay solutions to market.
Surmodics is led by President and Chief Executive Officer Richard Carlin, who has overseen strategic partnerships and product launches since taking the helm in 2016. The company maintains a governance structure aimed at innovation and regulatory compliance, with a board comprised of directors experienced in medical technology, life sciences, and global business operations. Through ongoing investment in R&D and customer-driven development, Surmodics seeks to address clinical challenges and improve patient outcomes worldwide.
